牛牛AI助理已提取核心訊息
Allarity Therapeutics, Inc., a biotechnology company incorporated in Delaware, has filed a Form D Notice of Exempt Offering of Securities with the SEC, indicating a new notice for an offering of securities. The filing, dated January 18, 2024, reports that the company has already sold $400,000 worth of senior convertible promissory notes to one accredited institutional investor. The total offering amount is listed as $1,400,000, with $1,000,000 remaining to be sold. The offering is not being made in connection with a business combination transaction and is expected to last less than one year. Allarity Therapeutics has claimed an exemption under Rule 506(b) and has declined to disclose its revenue range or aggregate net asset value. The company's principal place of business is in Boston, Massachusetts, and the executive officers and directors listed include Thomas Jensen, Joan Brown, Gerald McLaughlin, Laura Benjamin, and Joseph Vazzano. The proceeds from the offering are not intended for payments to any of the named executive officers, directors, or promoters.
Allarity Therapeutics, Inc., a biotechnology company incorporated in Delaware, has filed a Form D Notice of Exempt Offering of Securities with the SEC, indicating a new notice for an offering of securities. The filing, dated January 18, 2024, reports that the company has already sold $400,000 worth of senior convertible promissory notes to one accredited institutional investor. The total offering amount is listed as $1,400,000, with $1,000,000 remaining to be sold. The offering is not being made in connection with a business combination transaction and is expected to last less than one year. Allarity Therapeutics has claimed an exemption under Rule 506(b) and has declined to disclose its revenue range or aggregate net asset value. The company's principal place of business is in Boston, Massachusetts, and the executive officers and directors listed include Thomas Jensen, Joan Brown, Gerald McLaughlin, Laura Benjamin, and Joseph Vazzano. The proceeds from the offering are not intended for payments to any of the named executive officers, directors, or promoters.
在特拉華州註冊的生物技術公司Allarity Therapeutics, Inc. 已向美國證券交易委員會提交了D表格的證券豁免發行通知，其中指出了新的證券發行通知。該文件日期爲2024年1月18日，報告稱，該公司已經向一位合格機構投資者出售了價值40萬美元的優先可轉換期票。總髮行金額列爲140萬美元，還有100萬美元有待出售。此次發行與企業合併交易無關，預計將持續不到一年。Allarity Therapeutics已根據第506（b）條申請豁免，並拒絕透露其收入範圍或總淨資產價值。該公司的主要營業地點位於馬薩諸塞州波士頓，上市的執行官和董事包括托馬斯·詹森、瓊·布朗、傑拉爾德·麥克勞克林、勞拉·本傑明和約瑟夫·瓦扎諾。此次發行的收益不用於向任何指定的執行官、董事或發起人付款。
在特拉華州註冊的生物技術公司Allarity Therapeutics, Inc. 已向美國證券交易委員會提交了D表格的證券豁免發行通知，其中指出了新的證券發行通知。該文件日期爲2024年1月18日，報告稱，該公司已經向一位合格機構投資者出售了價值40萬美元的優先可轉換期票。總髮行金額列爲140萬美元，還有100萬美元有待出售。此次發行與企業合併交易無關，預計將持續不到一年。Allarity Therapeutics已根據第506（b）條申請豁免，並拒絕透露其收入範圍或總淨資產價值。該公司的主要營業地點位於馬薩諸塞州波士頓，上市的執行官和董事包括托馬斯·詹森、瓊·布朗、傑拉爾德·麥克勞克林、勞拉·本傑明和約瑟夫·瓦扎諾。此次發行的收益不用於向任何指定的執行官、董事或發起人付款。
有用
沒用
